Home

Loading...

Table of contents

Cryptococcal meningitis

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of cryptococcal meningitis are prepared by our editorial team based on guidelines from the Infectious Diseases Society of America (IDSA/CDC/NIH/HIVMA 2024), the World Health Organization (WHO 2022), and the Infectious Diseases Society of America (IDSA 2010). ...
Show more

Screening and diagnosis

Indications for screening
As per CDC/HIVMA/IDSA/NIH 2024 guidelines:
Obtain routine surveillance testing for serum cryptococcal antigen in patients with newly diagnosed HIV with no overt clinical signs of meningitis, if the CD4 counts are ≤ 100 cells/mm³, especially if ≤ 50 cells/mm³.
B
Obtain prompt CSF evaluation for CNS infection in patients with a positive test (BIII), particularly when the serum cryptococcal antigen lateral flow assay titer is ≥ 1:160.
B
Create free account

Diagnostic investigations

Antigen testing
As per WHO 2022 guidelines:
Obtain rapid serum, plasma or whole-blood cryptococcal antigen testing as the preferred diagnostic approach if both access to a cryptococcal antigen assay and rapid results (< 24 hours) are available in settings without immediate access to lumbar puncture or when lumbar puncture is clinically contraindicated.
B
Consider referring for further investigation and treatment promptly if a cryptococcal antigen assay is not available and/or rapid access to results is not ensured in settings without immediate access to lumbar puncture or when lumbar puncture is clinically contraindicated.
B

Diagnostic procedures

Lumbar puncture: as per WHO 2022 guidelines, perform s prompt lumbar puncture with measurement of CSF opening pressure and rapid cryptococcal antigen assay as the preferred diagnostic approach in adult, adolescent
B
and pediatric patients with HIV suspected of having a first episode of CM.
B
Show 2 more

Medical management

Antifungal therapy, induction, HIV-positive: as per CDC/HIVMA/IDSA/NIH 2024 guidelines, initiate IV amphotericin B in combination with oral flucytosine as induction therapy in patients with CM.
A
Show 5 more

More topics in this section

  • Antifungal therapy, induction (organ transplant recipients)

  • Antifungal therapy, induction (HIV-negative, non-transplant recipients)

  • Antifungal therapy, consolidation (HIV-positive)

  • Antifungal therapy, consolidation (organ transplant recipients)

  • Antifungal therapy, consolidation (HIV-negative, non-transplant recipients)

  • Antifungal therapy, maintenance (HIV-positive)

  • Antifungal therapy, maintenance (organ transplant recipients)

  • Antifungal therapy, maintenance (HIV-negative, non-transplant recipients)

  • ART

  • Diuretics and corticosteroids

  • Management of medication adverse effects

  • Management of treatment failure

  • Management of relapse

Therapeutic procedures

CSF drainage: as per CDC/HIVMA/IDSA/NIH 2024 guidelines, take measures to decrease ICP in all patients with confusion, blurred vision, papilledema, lower extremity clonus, or other neurologic signs indicative of increased ICP. Perform drainage of CSF via lumbar puncture for initial management.
B
Show 4 more

More topics in this section

  • Ventriculoperitoneal shunting

Specific circumstances

Pediatric patients: as per IDSA 2010 guidelines, initiate amphotericin B deoxycholate 1 mg/kg/day IV plus flucytosine 100 mg/kg/day PO in 4 divided doses for 2 weeks (follow the treatment length schedule for adults in non-HIV-infected, non-transplant patients) followed by fluconazole 10-12 mg/kg/day PO for 8 weeks as induction and consolidation therapy in pediatric patients with CNS disease.
B
Show 2 more

More topics in this section

  • Pregnant patients

  • Patients with immune reconstitution inflammatory syndrome

  • Patients with cerebral cyptococcomas

  • Patients with Cryptococcus gattii infection

  • Resource-limited healthcare environments

Preventative measures

Primary prophylaxis, HIV-positive: as per CDC/HIVMA/IDSA/NIH 2024 guidelines, do not initiate primary prophylaxis in HIV-positive patients in the US in the absence of a positive serum cryptococcal antigen test because of the relative infrequency of cryptococcal disease, lack of survival benefit associated with prophylaxis, possibility of drug-drug interactions, potential development of antifungal drug resistance, and costs.
D
Show 4 more

Follow-up and surveillance

Assessment of treatment response: as per CDC/HIVMA/IDSA/NIH 2024 guidelines, do not monitor serum or CSF cryptococcal antigen titers for determination of initial response to therapy.
D